| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1040691 | Functional | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 2. | ALA1040692 | Functional | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 3. | ALA1040693 | Toxicity | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | ALA1156829 | cell-based format | Novartis Malaria Screening | |
| 4. | ALA1040694 | Functional | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | ALA1156829 | assay format | Novartis Malaria Screening | ||
| 5. | ALA1789905 | Functional | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | Plasmodium yoelii | 4,416 | ALA1789904 | organism-based format | Novartis Malaria Screening | |
| 6. | ALA1963973 | Functional | PUBCHEM_BIOASSAY: Dose Response with BCECF Assay for V-ATPase inhibitors that increase vacuolar pH, Powder Set 1. (Class of assay: confirmatory) | 7 | ALA1201862 | assay format | PubChem BioAssays | ||
| 7. | ALA1964041 | Functional | PUBCHEM_BIOASSAY: Dose Response of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin, Powder Set1. (Class of assay: confirmatory) | 6 | ALA1201862 | assay format | PubChem BioAssays |
The page will load shortly, Thanks for your patience!